Serum human epididymis Protein-4 outperforms conventional biomarkers in the early detection of non-small cell lung cancer.

IF 4.6 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2024-10-19 eCollection Date: 2024-11-15 DOI:10.1016/j.isci.2024.111211

Mohammad Erfan Zare, Atefeh Nasir Kansestani, Xuanlan Wu, Lin Zhou, Jie Lu, Jun Huang, Yanzhong Wang, Yilei Ma, Yuzhen Gao, Jun Zhang

{"title":"Serum human epididymis Protein-4 outperforms conventional biomarkers in the early detection of non-small cell lung cancer.","authors":"Mohammad Erfan Zare, Atefeh Nasir Kansestani, Xuanlan Wu, Lin Zhou, Jie Lu, Jun Huang, Yanzhong Wang, Yilei Ma, Yuzhen Gao, Jun Zhang","doi":"10.1016/j.isci.2024.111211","DOIUrl":null,"url":null,"abstract":"<p><p>We employed a three-step approach to evaluate serum immunoassay-based biomarkers for detecting non-small cell lung cancer (NSCLC). In the first step, we performed a systematic review and meta-analysis and implemented the Laboratory Medicine Best Practices (LMBP) method to identify potential biomarkers. From potential biomarkers, Carcinoembryonic antigen (CEA), cytokeratin 19-fragments (Cyfra 21-1), and human epididymis protein-4 (HE4) were categorized as LMBP \"recommend.\" In the second step, we conducted matched-case-control validation on these recommended biomarkers and SAA, identified as the most accurate in the first step. In the third step, a re-meta-analysis was performed by integrating our experimental results and considering covariates. The final results revealed that HE4 emerged as the most reliable biomarker, offering balanced sensitivity and specificity, with accuracy unaffected by tumor stage, making it suitable for early diagnosis. Our findings support the inclusion of HE4 in clinical guidelines for NSCLC diagnosis, alongside well-established biomarkers such as Cyfra 21-1 and CEA.</p>","PeriodicalId":342,"journal":{"name":"iScience","volume":"27 11","pages":"111211"},"PeriodicalIF":4.6000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550588/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1016/j.isci.2024.111211","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/15 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

We employed a three-step approach to evaluate serum immunoassay-based biomarkers for detecting non-small cell lung cancer (NSCLC). In the first step, we performed a systematic review and meta-analysis and implemented the Laboratory Medicine Best Practices (LMBP) method to identify potential biomarkers. From potential biomarkers, Carcinoembryonic antigen (CEA), cytokeratin 19-fragments (Cyfra 21-1), and human epididymis protein-4 (HE4) were categorized as LMBP "recommend." In the second step, we conducted matched-case-control validation on these recommended biomarkers and SAA, identified as the most accurate in the first step. In the third step, a re-meta-analysis was performed by integrating our experimental results and considering covariates. The final results revealed that HE4 emerged as the most reliable biomarker, offering balanced sensitivity and specificity, with accuracy unaffected by tumor stage, making it suitable for early diagnosis. Our findings support the inclusion of HE4 in clinical guidelines for NSCLC diagnosis, alongside well-established biomarkers such as Cyfra 21-1 and CEA.

查看原文本刊更多论文

血清人类附睾蛋白-4在早期检测非小细胞肺癌方面优于传统生物标记物

我们采用了一种三步法来评估基于血清免疫测定的生物标记物，以检测非小细胞肺癌（NSCLC）。第一步，我们进行了系统综述和荟萃分析，并采用实验室医学最佳实践（LMBP）方法来确定潜在的生物标志物。从潜在的生物标记物中，癌胚抗原（CEA）、细胞角蛋白19-片段（Cyfra 21-1）和人类附睾蛋白-4（HE4）被归类为LMBP "推荐"。第二步，我们对这些推荐的生物标记物和在第一步中被确定为最准确的 SAA 进行了匹配病例对照验证。第三步，通过整合我们的实验结果并考虑协变量，重新进行了元分析。最终结果显示，HE4 是最可靠的生物标记物，其灵敏度和特异性达到了平衡，准确性不受肿瘤分期的影响，因此适用于早期诊断。我们的研究结果支持将 HE4 与 Cyfra 21-1 和 CEA 等成熟的生物标记物一起纳入 NSCLC 诊断的临床指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.